Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 trial of clofarabine plus standard induction chemotherapy in adults with previously untreated AML or high-risk MDS (RAEB)
2009-011613-24Phase 2Completed
- Sponsor
- HOVON
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of clofarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoint: Clinical efficacy of clofarabine in combination with induction cycles I and II. Started Jul 2009; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2009-011613-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011613-24.